Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) FCF Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed FCF Margin for 17 consecutive years, with 2.81% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 139.0% to 2.81% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.67%, a 163.0% increase, with the full-year FY2025 number at 1.67%, up 163.0% from a year prior.
  • FCF Margin was 2.81% for Q4 2025 at Myriad Genetics, down from 8.9% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 37.38% in Q1 2021 to a low of 32.91% in Q4 2023.
  • A 5-year average of 10.12% and a median of 10.88% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -6940bps in 2022, then soared 3433bps in 2024.
  • Myriad Genetics' FCF Margin stood at 8.02% in 2021, then plummeted by -54bps to 12.32% in 2022, then tumbled by -167bps to 32.91% in 2023, then skyrocketed by 104bps to 1.42% in 2024, then surged by 97bps to 2.81% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's FCF Margin are 2.81% (Q4 2025), 8.9% (Q3 2025), and 7.7% (Q2 2025).